16 news items
Takeda To Present Long-Term Data From Phase 3 ADVANCE-CIDP 3 Clinical Trial Of HYQVIA In Patients With Chronic Inflammatory Demyelinating Polyneuropathy At PNS Annual Meeting
TAK
18 Jun 24
-CIDP 3 clinical trial, a long-term extension study evaluating the safety and efficacy of HYQVIA® [Immune Globulin Infusion 10% (Human
Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA® in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting
TAK
18 Jun 24
the safety and efficacy of HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human
Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
AAN
AGRI
ALLG
17 Jun 24
. (NASDAQ:MBIO) shares jumped 145% to $0.32 after the company announced safety and efficacy data from the complete Waldenstrom Macroglobulinemia
Takeda Announced Topline Data From SKYLINE And SKYWAY Phase 3 Studies Of Soticlestat (TAK-935) Plus Standard Of Care Versus Placebo Plus Standard Of Care For Refractory Dravet Syndrome, Both The Studies Missed Their Primary Endpoints
OVID
TAK
17 Jun 24
Primary Endpoint of Reduction in Major Motor Drop Seizures
Soticlestat Showed a Consistent and Favorable Safety and Tolerability Profile
Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome
TAK
17 Jun 24
Soticlestat Showed a Consistent and Favorable Safety and Tolerability Profile
84i4e2w8fr6g22qb7g0uwf4mhz75h9fhk6htx 9hmp66aor0fq
TAK
14 Jun 24
exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like
jwaq37rsa38u2jkxoewe5jlqz8l6h3t4oa 8f9qnh1nx5f7ezh
TAK
3 Jun 24
– Safety Results Indicated TAK-861 is Generally Safe and Well
fqvs1 uhfohfuo
PFE
TAK
1 Jun 24
Conducted by GHSG Reported ADCETRIS + ECADD Combination Improved Progression-Free Survival, Showing Superior Efficacy and Tolerable Safety Profile
psv6 f2xrxip7e1g0jdu9qsr9rk7
TAK
31 May 24
by the totality of evidence including the interim analysis of efficacy, pharmacokinetic, safety and tolerability data from the first randomized, controlled open
p9obt9 hktvz3bvuotfh2tz
ACIU
TAK
13 May 24
investigated in the ongoing ABATE randomized, double-blind, placebo-controlled Phase 1b/2 trial to assess the safety, tolerability, immunogenicity
rxsz9n2kx9zr2ljhbe4hkhy4p4kijm u8h23iiew132
ACIU
TAK
13 May 24
in the ongoing ABATE randomized, double-blind, placebo-controlled Phase 1b/2 trial to assess the safety, tolerability, immunogenicity and pharmacodynamic
miesjk2w4moy7e08ukqrkcfy02 a4b2bqh6wqt7ape8abvzij664yu
TAK
9 May 24
rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel
tiy3erlmmg4bp5r9q43h6i3yjidh6tfbt ceiy63n13hkfdi9eug80tmp9ck
TAK
26 Apr 24
they received. Fruquintinib demonstrated a manageable safety profile in FRESCO-2. Adverse reactions leading to treatment discontinuation occurred in 20
8udlvsbx
TAK
26 Apr 24
of therapies they received. Fruquintinib demonstrated a manageable safety profile in FRESCO-2. Adverse reactions leading to treatment discontinuation occurred
6svj2yxmv6p1pmrq9e21paivxpm3jiyke2pudybpay52
TAK
18 Apr 24
is based on the VISIBLE 2 Study (SC CD Trial), a Phase 3, randomized, double-blind, placebo-controlled trial, which assessed the safety and efficacy of an SC
dzkkkl8q43zz
TAK
26 Mar 24
of the evidence provided from an interim analysis of efficacy, pharmacokinetic, safety and tolerability data from the first randomized, controlled, open-label
- Prev
- 1
- Next